ecrin-mdr-crcClinical2018Colorectal cancer, Gastric cancer, Esophageal cancer, Biliary tract cancer, Pancreatic cancer, and Other gastrointestinal cancerColorectal Cancer, Gastric Cancer, Esophageal Cancer, Biliary Tract Cancer, Pancreatic Cancer, And Other Gastrointestinal CancerInterventionalhttps://newmdr.ecrin.org/Study/2648298Japan9ECRIN MDRActive, not recruitingfalseA multicenter phase II study of Nivolumab monotherapy in recurrent and/or metastatic gastrointestinal cancer patients with high Tumor Mutation Burden (TMB-H)Interventions: Monotherapy with Nivolumab 360 mg, every 3 weeks intravenous administration Primary outcome(s): Objective response rate (ORR) determined by RECIST v1.1 Study Design: Single arm Non-randomized2018-09-152648298JPRN-UMIN000033182